MannKind stock rises 4.54 percent on Nasdaq at EUR 2.81

Published on 10/15/2026 at 21:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Truist set USD 5.00 on October 7, 2026. MannKind stock costs EUR 2.81 on October 15, 2026, up 4.54 percent on Nasdaq.

Nasdaq gain and target

MannKind posted a 4.54 percent Nasdaq gain on October 15, 2026.
Truist set a USD 5.00 target on October 7, 2026.
MannKind stock costs EUR 2.81 at Lang & Schwarz on October 15, 2026 at 8:49 p.m. CEST, 4.54 percent higher on Nasdaq against the previous close.
The next quarterly communication is scheduled for November 4, 2026.

MNKD, US56400P7069, Illustration mit AI erstellt.

MannKind stock rose 4.54 percent on Nasdaq on October 15, 2026, while the euro quote stood at EUR 2.81 in after-hours trading. The move places the stock above its Nasdaq previous close, while the latest analyst target remains a separate valuation reference.

MarketBeat reported that Truist Financial cut its target for MannKind from USD 6.00 to USD 5.00 on October 7, 2026, while maintaining a Buy rating. The target is above the latest Nasdaq quote of USD 3.16.

Revenue grew in the second quarter

MannKind reported second-quarter 2026 revenue of USD 109.37 million, up 43.00 percent from the prior-year period, according to MarketBeat. Adjusted earnings per share were a loss of USD 0.01, matching the consensus estimate of a USD 0.01 loss.

52-week range leaves room

The Nasdaq quote was USD 3.16 on October 15, 2026 at 2:57 p.m. ET, with a session range of USD 3.00 to USD 3.16. MannKind stood 51.46 percent below its 52-week high of USD 6.51 and 41.70 percent above its 52-week low of USD 2.23.

Valuation and November 4 date

The latest market capitalization was USD 1.0 billion, while the trailing P/E ratio was minus 23.02. The company calendar lists November 4, 2026 as the next quarterly communication, according to wallstreetONLINE.

Comparison with peers

MannKind (Nasdaq, USD): plus 4.54 percent, P/E minus 23.02, market capitalization USD 1.0 billion
United Therapeutics (Nasdaq, USD): plus 1.36 percent, P/E 19.61, market capitalization USD 23.5 billion
Insulet (Nasdaq, USD): plus 3.33 percent, P/E 25.88, market capitalization USD 9.6 billion

Euro quote after the Xetra close

The euro quotation gives German investors a separate trading reference from the Nasdaq listing. At Lang & Schwarz, MannKind was trading at EUR 2.81 on October 15, 2026 at 8:49 p.m. CEST, after the Xetra close. The Nasdaq quote was USD 3.16 at 2:57 p.m. ET on the same date.

The further course of trading is shown by the continuously updated real-time quote of MannKind stock.